Lecanemab Shows Strong Long-Term Adherence in Real-World Data
Event summary
- Eisai presented real-world data at the 2026 AD/PD™ Congress showing 67.3% of early Alzheimer's patients continued lecanemab treatment at 24 months.
- BioArctic's Professor Lars Lannfelt detailed lecanemab's binding profile and immune pathway engagement in Alzheimer's disease brain tissue.
- BioArctic's Ebba Amandius presented data on the successful use of alpha-synuclein seed amplification assay (SAA) for patient stratification in the exidavnemab trial.
- Lecanemab is approved in 53 countries and under regulatory review in 6 others, with subcutaneous formulations under review in the US and China.
The big picture
BioArctic's long-term collaboration with Eisai continues to yield critical data supporting lecanemab's efficacy in real-world settings. The strong adherence rates observed in early Alzheimer's patients underscore the drug's potential to become a cornerstone treatment. Meanwhile, BioArctic's advancements in alpha-synuclein targeting highlight its broader ambitions in neurodegenerative disease therapy. The company's strategic focus on both amyloid and synuclein pathways positions it at the forefront of neuroscience innovation.
What we're watching
- Regulatory Progress
- The pace at which subcutaneous formulations of lecanemab gain approval in key markets like the US and China.
- Clinical Efficacy
- How long-term adherence data translates into sustained clinical benefits for Alzheimer's patients.
- Pipeline Development
- The success of BioArctic's exidavnemab trial and its potential impact on Parkinson's disease treatment.